Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 5, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 673,000 ordinary shares of 25 pence each.
- Purchase Price: 1,488.229 pence per share.
- Treasury Holdings: 169,207,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,813,095,019 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the open market purchase of 673,000 shares on June 5, 2006. This action increased the company's Treasury share count. No other material changes to operations or financial position are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 673,000 shares by the price of 1,488.229 pence.
- Confirm the updated total share capital structure (5,813,095,019 issued shares plus 169,207,678 Treasury shares).
- Check subsequent filings to determine if the Treasury shares were retired or retained for future use.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.